精神分裂症患者骨代谢标志物的研究

Abstract
Figure/Table
References (22)
Related Citation (4)

Download: PDF (0 KB) HTML (26 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo explore the levels of bone metabolism markers in first-episode schizophrenia without treatment and schizophrenia who were treated with atypical antipsychotics.MethodsFirst-episode,treated with atypical antipsychotics schizophrenia and healthy controls were chosen to participate this study from April 2016 to October.These patients were outpatient or in-patient and each group included 40.The blood concentrations of bone metabolism markers of 3 groups,including OC,PTH,PTNP,VitD-T and β -CTX were compared.ResultsLevels of OC,PTNP and β -CTX in first-episode and treatment groups were higher than the control group and the differences were significant(P＜0.01).Levels of VitD-T and PTH were lower than the control group and the differences were significant(P＜0.01).β-CTX blood concentration in the first-episode group was higher than the treatment group,and the difference was significant(P＜0.01)ConclusionThe levels of bone metabolism markers in first-episode schizophrenia are abnormal and clinical workers should take measures to prevent the risk of fracture.

Key words： Schizophrenia Bone metabolism markers Difference Antipsychotics

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Yong
	WAN Jing
	PING Jun-jiao
	XUE Kun-xi
	REN Yan-zhen
	HUANG Cai-ying
	DU Bao-guo

Cite this article:

WU Yong,WAN Jing,PING Jun-jiao, et al. The study of bone metabolism markers in schizophrenia[J]. 中国当代医药, 2018, 25(3): 120-122.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I3/120

[1]	Howard L，Kirkwood G，Leese M.Risk of hip fracture in patients with a history of schizophrenia[J].Br J Psychiatry，2007，190：129-134.
[11]	王秀珍，高剑锋，马骥.奥氮平治疗首发精神分裂症的血清心肌标志物比较[J].中国医药科学，2012，2（9）：55.
[12]	程晓光，李勉文，李娜，等.定量 CT 骨密度测量（QCT）在骨质疏松症诊治中的临床应用，2007国际临床骨密度学会（ISCD）共识摘录[J].中国骨质疏松杂志，2012，18（11）：969-974.
[14]	Radaei F，Darvishi A，Gharibzadeh S.The correlation between osteoporosis occurrences in both schizophrenia and parkinson′s disease[J].Front Neurol，2014，5：83.
[2]	Kishimoto T，De Hert M，Carlson HE，et al.Osteoporosis and fracture risk in people with schizophrenia[J].Curr Opin Psychiatry，2012，25（5）：415-429.
[3]	Kishimoto T，Watanabe K，Takeuchi H，et al.Bone mineral density measurement in female in patients with schizophrenia[J].Schizophr Res，2005，77（1）：113-115.
[4]	Crews MP，Howes OD.Is antipsychotic treatment linked to low bonemineraldensityandosteoporosisAreviewoftheevidence and the clinical implications[J].Hum Psychopharmacol，2012，27（1）：15-23.
[5]	Howes OD，Wheeler MJ，Meaney AM，et al.Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment[J].J Clin Psychopharmacol，2005，25（3）：259-261.
[6]	Lee TY，hung MY，Chung HK，et al.Bone density in chronic schizophrenia with long-term antipsychotic treatment：preliminary study[J].Psychiat Invest，2010，7（4）：278-284.
[7]	O Keane V.Antipsychotic-induced hyperprolactinaemia，hypogonadism and osteoporosis in the treatment of schizophrenia[J].J Psychopharmacol，2008，22（2 Suppl）：70-75.
[8]	Baastrup PC，Christiansen C，Transbol I.Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy[J].Neuropsychobiology，1980，6（1）：56-59.
[9]	Meaney AM，Smith S，Howes OD，et al.Effects of long term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia[J].Br J Psychiatry，2004，184：503-508.
[10]	Abraham G，Paing WW，Kaminski J，et al.Effects of elevated serum prolactin on bone mineral density and bone mineral densityandbonemetabolisminfemalepatientswithschizophrenia： a prospective study[J].Am J Psychiatry，2003，160（9）：1618-1620.
[13]	Papaioannou A，Morin S，Cheung AM，et al.2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada： summary[J].CMAJ，2010，182（17）：1864-1873.
[15]	Jung DU，Kelly DL，Oh MK，et al.Bone mineral density and osteoporosis risk in older patients with schizophrenia[J].Clin Clin Psychopharmacol，2015，9（1）：36-39.
[16]	Hirschmann S，Gibel A，Tsvelikhovsky I，et al.Late-onset psychosis and risedronate treatment for osteoporosis[J].Clin Schizophr Relat Psychoses，2011，31（4）：406-410.
[17]	李晓一，陈虹，陈杏丽，等.利培酮治疗首发精神分裂症患者1年骨密度变化的病例对照研究[J].上海精神医学，2011， 23（5）：278-283.
[18]	吴勇，平军娇，杜宝国，等.非典型抗精神病药对精神分裂症患者骨代谢的影响[J].临床精神医学杂志，2017，27（4）：272-274.
[19]	Crews M，Lally J，Gardner-Sood P，et al.Vitamin D deficiency in first episode psychosis：a case-control study[J].Schizophr Res，2013，150（2-3）：533-537.
[20]	侯敏，唐茂芹，米国琳，等.精神分裂症患者骨密度影响因素研究[J].中国骨质疏松杂志，2011（12）：1073-1076.
[21]	付飞.精神疾病患者住院期间40例骨折的原因及预防[J].中国民康医学，2011（11）：1373-1374.
[22]	党瑞丽，汪沛，李焕德，等.抗精神病药对大鼠体内维生素 D 代谢的影响研究[J].中南药学，2014，12（9）：841-843.